Instrumento Inactivo

Acciones Cubist Pharmaceuticals Inc

Acciones

Precio de cierre Nasdaq Otros sitios de cotización
- ^USD	-

Cubist Pharmaceuticals : Announces Withdrawal of Listing of CVRs (CBSTZ) from NASDAQ Global Select Market	13/01/15
Cubist Pharmaceuticals : meldet FDA-Zulassung seines neuen Antibiotikums ZERBAXA™ (Ceftolozan/Tazobactam) für komplizierte Harnwegsinfektionen und komplizierte intraabdominelle Infektionen	21/12/14
Cubist Pharmaceuticals : annonce l’approbation par la FDA du nouvel antibiotique ZERBAXA™ (ceftolozane/tazobactam) pour le traitement des infections urinaires compliquées et des infections intra-abdominales compliquées	20/12/14
Cubist Pharmaceuticals : Announces FDA Approval of New Antibiotic ZERBAXA™ (Ceftolozane/Tazobactam) for Complicated Urinary Tract and Complicated Intra-abdominal Infections	20/12/14
Cubist Pharmaceuticals : sales force seen as potential boon for Merck intestinal drug	10/12/14

Directores	Puesto	Edad	Desde
Karen Rogers PRN	Corporate Officer/Principal	-	-
Phyllis Rae Abbuhl SAM	Sales & Marketing	-	-
Frederick B. Oleson PRN	Corporate Officer/Principal	-	01/01/97

Administradores	Puesto	Edad	Desde
Martin Hermanus Soeters BRD	Director/Board Member	70	01/09/06
Kenneth J. Martin BRD	Director/Board Member	70	25/09/13

Sector

	Varia. 1 de ene.	Capi.
CSL LIMITED	+0,10 %	91,42 mil M
SAMSUNG BIOLOGICS CO.,LTD.	+2,76 %	41,08 mil M
BIOGEN INC.	-9,06 %	34,26 mil M
UCB	+53,99 %	25,27 mil M
BIOMARIN PHARMACEUTICAL INC.	-16,61 %	15,27 mil M
INCYTE CORPORATION	-9,14 %	12,81 mil M
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-12,11 %	11,6 mil M
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-43,61 %	11,42 mil M
SWEDISH ORPHAN BIOVITRUM AB	+3,67 %	9155,92 M